# Celltrion/Humasis Covid-19 rapid test kit cleared for emergency use in U.S.

The DiaTrust Covid-19 IgG/IgM Rapid Test, jointly developed by Celltrion and Humasis, received FDA emergency use authorization. Celltrion USA also signed a $214.5 million supply contract with Prime Healthcare Distributors.

- Type: Regulation
- Announced: 2021-04-19
- Where: United States
- Value: $214.5M
- Status: completed
- Products: Covid-19 rapid test kit
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Celltrion](https://endata.com/companies/15585.md)
- [Celltrion USA](https://endata.com/companies/50913.md)
- [Prime Healthcare Distributors](https://endata.com/companies/50908.md) (customer)
- [Humasis](https://endata.com/companies/54536.md) (partner)

## Sources

- [pulse.mk.co.kr](https://pulse.mk.co.kr/news/all/9837353), 2021-04-19: "DiaTrust is a product for healthcare professionals designed to recognize a specific surface antigen of the coronavirus for the diagnosis of infection within 15 minutes."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.